Novabay Pharmaceuticals Inc
NBY
Get informed when a big investor buys or sells
+ FollowMarket Cap$39.14M
Close$
$1.23
16% downside
Current Fair Value
16% downsideOvervalued by 16% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $39.14 Million |
|---|---|
| Enterprise Value | $32.17 Million |
| Dividend Yield | $4.00 (347.83%) |
| Earnings per Share | $-3.8 |
| Beta | 0.16 |
| Outstanding Shares | 31,048,000 |
Return
| Return on Equity | 379.93% |
|---|---|
| Return on Assets | 379.13% |
| Return on Invested Capital | -16.56% |
Valuation & Multiples
| P/E Ratio | 0.06 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.37 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.53 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 1, 2026
EPS Estimate
$-1.00
Average shareholder expectationRevenue Estimate
$3.60 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.30%▼ 14.64% |
|---|---|
| Total Invested | $2.44M▼ 92.90% |
| Investors Holding | 24▼ 2.00% |
ESG Score
No data
About Novabay Pharmaceuticals Inc
CEO: Justin Hall